Reference Work Entry

Encyclopedia of Metalloproteins

pp 1822-1829

Proteomic Basis of Cisplatin Resistance

  • Juan D. ChavezAffiliated withDepartment of Genome Sciences, University of Washington
  • , James E. BruceAffiliated withDepartment of Genome Sciences, University of Washington Email author 


Protein interaction network; Resistance of platinum anticancer drugs


Cisplatin along with other platinum-based drugs including oxaliplatin, carboplatin are some of the most widely used chemotherapeutic agents. Unfortunately, drug resistance remains a major problem for the successful chemotherapeutic treatment of cancer. Current evidence suggests that resistance toward platinum chemotherapeutics is a multifactorial problem due to changes in the expression levels and activities of a wide number of proteins.

Cisplatin Resistance and Changes to the Proteome

The primary goal of cancer chemotherapy is to disrupt tumor cell growth by interfering with cell division (mitosis) or activating programmed cell death pathways (apoptosis). The powerful anticancer properties of cisplatin ((SP-4-2)-diamminedichloridoplatinum, cis-PtCl2(NH3)2) were first discovered by accident in a series of studies carried out in the 1960s ...

This is an excerpt from the content